SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sigyn Therapeutics, Inc.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.03+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $48.16K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Sigyn Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Sigyn Therapeutics filed with the SEC
NOTE PURCHASE AGREEMENT (this “ Agreement ”), dated as of August 8, 2025, (the “ Execution Date ”),
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
CEO Note: Combating the Rising Threat of New Pandemic Viruses
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Releases Letter to Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
Regulation FD disclosure · EX-99.1 to Form 8-K
Marleau, Ph.D. as Chief Scientific Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics™ Announces Completion of Animal Studies
Other events · EX-99.1 to Form 8-K